3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
57
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
Paclitaxel
15
Carboplatin
9
liposomal doxorubicin
8
Bevacizumab
8
pembrolizumab
7
Topotecan
6
olaparib
4
mirvetuximab soravtansine
4
Nivolumab
4
Cyclophosphamide
4
niraparib
3
fludarabine
3
Gemcitabine
3
Drug Therapy
3
rucaparib
2
ribociclib
2
pegfilgrastim
2
palbociclib
2
oregovomab
2
fludarabine phosphate
2
Irinotecan
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fulvestrant
2
Cisplatin
2
Blood Specimen Collection
2
1-dodecylpyridoxal
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
isoquercitrin
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled